ABSTRACT
Background/aims Concerns have been expressed about the relationship between reduced levels of health care utilisation and the COVID-19 pandemic. This study aimed to elicit and explore the views of patients with neovascular age-related macular degeneration (nAMD) regarding the COVID-19 pandemic and their ophthalmic care.
Methods Between April 29th and September 4th 2020, semi-structured telephone interviews were conducted with thirty-five patients with nAMD taking part in a larger diagnostic accuracy study of home-monitoring tests. Participants were recruited using maximum variation sampling to capture a range of key characteristics including age, gender and time since initial treatment. Transcribed interview data were analysed using a deductive and inductive thematic approach.
Results Three themes emerged from the analysis: i. access to eye clinic care. ii. COVID-19 mitigating factors and care delivery and iii. social and personal circumstances. Participants reported anxieties about cancelled or delayed appointments, limited communication from clinic-based services about appointments, and the impact of this on their ongoing care. Despite these concerns, there was apprehension about attending appointments due to infection risk and a perception that nAMD patients are a ‘high risk’ group. Views of those who attended clinics during the study period were, however, positive, with social distancing and infection control measures providing reassurance.
Conclusions These findings contribute to our understanding about experiences of patients with nAMD during the COVID-19 pandemic and have potential implications for future planning of care services. Innovative approaches may be required to address issues related to access to care, including concerns about delayed or cancelled appointments.
Synopsis Perspectives of patients with neovascular age-related macular degeneration regarding the COVID-19 pandemic identified important issues regarding access to, and experience of ophthalmic care. These findings have implications for future planning of services.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
n/a
Funding Statement
This project was funded by the National Institute for Health Research, Health Technology Assessment (HTA) Programme (ref 15/97/02). The views and opinions are the authors and do not necessarily reflect the HTA programme, NIHR, NHS or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval Ethical approval was acquired from the National Research Ethics Service (IRAS ref: 232253 REC ref: 17/NI/0235).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
n/a
